Qwixel Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Qwixel Therapeutics General Information
Description
Developer of drugs based in Los Angeles, USA. The company developed immune cytokines drugs that combine antibodies with proteins that stimulate immune responses, enabling patients to improve their immunity.
Contact Information
Website
www.qwixelt.comCorporate Office
- 258 Denslow Avenue
- Los Angeles, CA 90049-3223
- United States
Corporate Office
- 258 Denslow Avenue
- Los Angeles, CA 90049-3223
- United States
Qwixel Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 01-Jan-2021 | Completed | Generating Revenue | |||
| 3. Grant | 05-Jun-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2019 | $10M | $10M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Qwixel Therapeutics Patents
Qwixel Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025084914-A | Fusion protein composition comprising targeted masked type i interferons (ifna and ifnb) and antibody against tumor antigen, for use in treatment of cancer | Pending | 15-Apr-2019 | ||
| US-11136353-B2 | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof | Active | 15-Apr-2019 | ||
| US-11795198-B2 | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof | Active | 15-Apr-2019 | ||
| US-20200331966-A1 | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof | Active | 15-Apr-2019 | ||
| US-20220056076-A1 | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof | Active | 15-Apr-2019 | A61K38/10 |
Qwixel Therapeutics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Magnify | Accelerator/Incubator | |||
| National Institutes of Health | Government |
Qwixel Therapeutics FAQs
-
When was Qwixel Therapeutics founded?
Qwixel Therapeutics was founded in 2016.
-
Where is Qwixel Therapeutics headquartered?
Qwixel Therapeutics is headquartered in Los Angeles, CA.
-
What industry is Qwixel Therapeutics in?
Qwixel Therapeutics’s primary industry is Drug Discovery.
-
Is Qwixel Therapeutics a private or public company?
Qwixel Therapeutics is a Private company.
-
What is Qwixel Therapeutics’s current revenue?
The current revenue for Qwixel Therapeutics is .
-
How much funding has Qwixel Therapeutics raised over time?
Qwixel Therapeutics has raised $10M.
-
Who are Qwixel Therapeutics’s investors?
Magnify and National Institutes of Health have invested in Qwixel Therapeutics.
-
When was Qwixel Therapeutics acquired?
Qwixel Therapeutics was acquired on 01-Jan-2021.
-
Who acquired Qwixel Therapeutics?
Qwixel Therapeutics was acquired by Nammi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process